Allogeneic CAR-T

Allogeneic CAR-T is the off-the-shelf donor-cell route discussed in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学. Instead of making a custom product from each patient’s own cells through Ex Vivo CAR-T Manufacturing, allogeneic CAR-T uses immune cells from healthy donors and prepares a product in advance.

The source presents this route as an attempt to solve time and cost, but 刘诚 is skeptical of its efficacy compared with autologous CAR-T Cell Therapy. His reason is immune persistence: cells from another person can be rejected by the patient’s immune system and may not stay alive long enough to deliver the same effect.

vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 reinforces the same caution from a separate industry-review source. 小P老师 says allogeneic CAR-T still appears weaker than autologous CAR-T in efficacy, making it an unsolved convenience-versus-performance tradeoff rather than a solved replacement.

Key Claims

• Allogeneic CAR-T tries to make cell therapy more available by separating production from a single patient’s treatment timeline.
• Liu argues that donor-cell rejection and limited persistence are the route’s central weaknesses.
• The route is conceptually different from In Vivo CAR-T, which still aims to modify the patient’s own cells inside the body.
• Vol.117 adds that allogeneic CAR-T’s weaker effect keeps alternative routes such as T-Cell Engagers and In Vivo mRNA CAR-T commercially interesting.

Connections

• CAR-T Cell Therapy - therapy class being adapted into an off-the-shelf format.
• Ex Vivo CAR-T Manufacturing - patient-specific autologous route allogeneic products try to replace or supplement.
• In Vivo CAR-T - separate cost/access route discussed in the same episode.
• Cancer Immune Recognition Problem - underlying oncology problem all CAR-T variants try to solve.
• T-Cell Engagers and In Vivo mRNA CAR-T - adjacent vol.117 alternatives and variants.